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Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for respiratory diseases among 
children under 5 years old. The aim of this study was to analyse RSV seasonality in the five distinct regions of 
Brazil using time series analysis (wavelet and Fourier series) of the following indicators: monthly positivity of the 
immunofluorescence reaction for RSV identified by virologic surveillance system, and rate of hospitalisations per 
bronchiolitis and pneumonia due to RSV in children under 5 years old (codes CID-10 J12.1, J20.5, J21.0 and J21.9). 
A total of 12,501 samples with 11.6% positivity for RSV (95% confidence interval 11 - 12.2), varying between 7.1 and 
21.4% in the five Brazilian regions, was analysed. A strong trend for annual cycles with a stable stationary pattern 
in the five regions was identified through wavelet analysis of the indicators. The timing of RSV activity by Fourier 
analysis was similar between the two indicators analysed and showed regional differences. This study reinforces the 
importance of adjusting the immunisation period for high risk population with the monoclonal antibody palivizumab 
taking into account regional differences in seasonality of RSV.
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Respiratory syncytial virus (RSV) is a non-segment-
ed enveloped RNA virus of the family Paramyxoviridae, 
genus Pneumovirus. Although RSV causes upper respi-
ratory tract diseases in patients of every age, more severe 
influenza-like illness occurs in children. Most children 
are infected during the first year of life, and almost all 
are infected before the age of 2 years (CDC 2014).
RSV is the leading cause of hospitalisation for respira-
tory diseases among children under 5 years of age, most 
commonly during the first year of life and almost all cases 
under 2 years. RSV has also been associated with asthma 
exacerbation, sibilance episodes, and invasive pneumo-
coccal disease (Dulek & Peebles Jr 2011, Lotz & Peebles 
2012, Régnier & Huels 2013, Weinberger et al. 2014).
The main factors associated with the severity of the in-
fection in infants under 5 years old are prematurity, congen-
ital heart disease, and chronic lung disease of prematurity 
(CID 2009). RSV reinfections throughout life are common, 
generally manifesting through influenza-like illness.
In Brazil, RSV was found in 23.1-42.2% of the infants 
hospitalised for lower respiratory tract diseases and was as-
sociated with 3.6% of the deaths (Salomão Jr et al. 2011, 
Lamarão et al. 2012). However, the lack of data on the role 
of RSV in the total number of hospitalisations and mortal-
ity by lower respiratory tract diseases in children under 5 
years old, especially in developing countries, complicate 
the evaluation of the global impact of the disease; therefore, 
it is difficult to better define the priorities and investments 
needed for prevention and treatment (Nair et al. 2010).
In temperate climates, RSV exhibits a clear seasonal 
incidence pattern, occurring mostly during winter (CID 
2009, Bloom-Feshbach et al. 2013). The seasonality in 
tropical and equatorial regions, in contrast, seems to be 
less marked (Piñeros et al. 2013, Stockman et al. 2013).
In Brazil, regional specificities in the seasonality 
of viral circulation were identified in the South (Porto 
Alegre) (Straliotto et al. 2002), Southeast (São Paulo) 
(Paiva et al. 2012), Northeast (Fortaleza) (Alonso et al. 
2012) and North (Belém) (Lamarão et al. 2012) regions. 
However there is still no comprehensive study of season-
ality across the country.
Despite improvements in RSV infection support-
ive care, no vaccine is available (Borchers et al. 2013, 
Haynes 2013). Monoclonal antibody prophylaxis has 
been shown to be effective in reducing the number of 
hospitalisations in children under 2 years of age with 
risk factors for aggravation (IMpact-RSV Study Group 
1998). However, the high cost of prophylaxis has limited 
its usage, especially in developing countries. Current 
protocols recommend a maximum of five consecutive 
monthly doses of palivizumab per year during the pe-
riod of greatest incidence of RSV (CID 2009, SBP 2011).
The aim of this study was to analyse the seasonal be-
havior of RSV and the temporal trend of hospitalisations 
for bronchiolitis and viral pneumonia caused by RSV in 
the five regions of Brazil. Identification of the periods 
of higher viral circulation in each region of the country 
will contribute to revision of the recommendations for 
prevention of RSV infection and the usage of immuno-
biologicals in the different regions of Brazil.
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MATERIALS AND METHODS
This was an ecologic study of the time series of RSV 
monthly positivity in samples tested using the influenza 
sentinel surveillance system (“SIVEP-Gripe” - SIVEP-
flu), with the purpose of identifying seasonal patterns in 
the five regions of Brazil from 2005-2012. The temporal 
trend of the rates of monthly hospitalisation for bronchi-
olitis and pneumonia in infants under 5 years of age, in 
the same regions and period, was also analysed.
All five administrative regions of Brazil were chosen 
as local of study because they present different socio-
economic and environmental patterns which may influ-
ence on virus circulation. The climate in the Midwest 
region (14,993,194 inhabitants) is predominantly tropi-
cal, with a rainy season between November and March 
(monthly rainfall between 13.1-255.6 × 10-3 m) and tem-
peratures ranging 22.0-26.4ºC. The Northeast region 
(55,794,694 inhabitants) has a semiarid climate in the 
interior and a tropical Atlantic climate near the coast, 
where the majority of the population is concentrated, 
with a monthly rainfall ranging 46.4-281.4 × 10-3 m 
and a low temperature range (monthly average of 25.1-
27.3ºC). The North region (16,983,485 inhabitants) has 
an equatorial climate with rainfall throughout the year 
(monthly rainfall between 74.4-303.9 × 10-3 m) and low 
thermal amplitude (averages 26.3-28.0ºC). The South-
east region (84,465,579 inhabitants) has a predominantly 
altitude tropical climate with rainfall concentrated be-
tween November and March (monthly rainfall between 
28.2-285.6 × 10-3 m) and a slightly higher thermal am-
plitude (monthly average between 18.7-24.6ºC). Finally, 
the Southern region (28,795,762 inhabitants) has a pre-
dominantly subtropical climate with rainfall distributed 
throughout the year (monthly rainfall between 101.1-
198.9 × 10-3 m) and lower temperatures between May 
and September (monthly average between 14.9-23.1ºC).
Influenza sentinel surveillance system data (SIVEP-
Gripe) - The laboratory data were obtained from 
SIVEP-Gripe, which has 128 sentinel surveillance units 
distributed throughout all the regions of Brazil. The sur-
veillance units record at least five samples of nasophar- 
yngeal secretions weekly from patients with influenza-
like illness (measured fever associated with sore throat 
and/or cough without age group distinction). Samples are 
processed by using indirect immunofluorescence (IIF), 
including tests for influenza A and B; parainfluenza 1, 
2 and 3; adenovirus; and RSV. The study variables in-
cluded place of residence, age, and positive and negative 
IIF results for RSV.
The laboratory positivity indicator was calculated 
using the results of the IIF reaction of the nasophar- 
yngeal secretion samples: monthly positivity of IIF reac-
tion for RSV, relative to the total of monthly valid tests, 
i.e., excluding the results within inadequate samples (not 
enough biological material, improper storage, correct 
material in the sample) or inconclusive results (no valid 
results). Because in some regions the number of samples 
was low until 2004 (Freitas et al. 2013), samples from 
2005-2012 were selected for analysis.
Hospitalisation data - The hospitalisation data were 
obtained from the Hospital Information System of the 
Ministry of Health, which includes all the admissions 
made by the Brazilian Public Health System through 
Hospitalisation Authorisation. These data include over 
75% of all hospitalisations in Brazil. The hospitalisation 
causes with a possible association to RSV were selected. 
These are codified in the information system as RSV-
associated pneumonia, RSV-associated acute bronchi-
tis, RSV-associated acute bronchiolitis and unspecified 
acute bronchiolitis, with the following respective codes 
from the International Disease Classification, CID-10: 
J12.1, J20.5, J21.0 and J21.9.
The hospitalisation rates were calculated by dividing 
the number of admissions of infants less than 5 years old 
(under the aforementioned causes) by the annual popula-
tion in the same age range, estimated by the Brazilian 
Institute of Geography and Statistics. The hospitalisation 
and population data were obtained from the Informatics 
Department of the Brazilian Public Health System.
Time series - Wavelet and Fourier analysis - Initially, 
plots were made to visualise time parameters and sea-
sonal trends. The IIF positivity proportions of nasopha-
ryngeal secretion from laboratory data and hospitalisa-
tion rates were analysed using the wavelet technique for 
identifying periodic patterns of RSV occurrence and 
associated morbidity. Wavelet analysis provides infor-
mation on the time-scale domain for stationary and non-
stationary events, allowing for simultaneous localisation 
of time and of high and low frequencies. Subtle time 
patterns of occurrence of phenomena of different nature 
can be detected, as well as changes in its periodicity. 
Wavelet analysis permits inferences regarding the way 
continuous variables relate to different frequencies and 
whether this relationship changes over time (Torrence & 
Compo 1998, Cazelles et al. 2007). The algorithms de-
scribed by Torrence and Compo (1998), available in free 
software were used (Alonso & McCormick 2012). This 
analysis allows establishing whether a specific periodic 
phenomenon has a stationary frequency, a basic assump-
tion required in Fourier analysis.
Next, the laboratory and hospitalisation data were 
analysed through Fourier time series decomposition 
using sinusoidal harmonics of the annual and semi-an-
nual cycles. Fourier analysis considers every period to 
have a periodic stable frequency throughout time. This 
method allows analysing signals and systems through 
decomposition of periodic functions in convergent trig-
onometric series (sin and cos). In this case, it allowed 
identifying the time of annual and biannual peaks of the 
time series analysed through multiple linear regression.
The possible occurrence of seasonal heterogeneity 
within the administrative regions was verified through 
Fourier analysis of the individual hospitalisation data of 
each state. Since the sole purpose of this study was the 
analysis of seasonality, secular trends in mortality and 
hospitalisations were corrected by means of polynomial 
regression to improve the regression fit.
Analysis of RSV transmission annual seasons - The 
probable annual stations of greater RSV circulation were 
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defined based on the laboratory-based positivity indicator 
of the samples. This indicator (monthly positive samples/
total of monthly valid samples) was used to define annual 
seasons of RSV as the five consecutive months in which 
higher IIF positivity was observed. This definition is con-
sistent with the prophylaxis of five consecutive monthly 
doses of palivizumab, as recommended by the Brazilian 
Pediatric Society (SBP 2011). This criterion, with minor 
changes, has been used before to study RSV and influ-
enza through analysis of monthly and weekly data, and 
has been shown to be adequate for the study of seasonality 
(Chiu et al. 2002, Bloom-Feshbach et al. 2013).
Fourier and wavelets analysis were performed using 
Matlab (Mathworks Inc.) software EPIPOI® (Alonso & 
McCormick 2012). Statistical analysis was performed 
using SPSS v. 13.0 (SPSS Inc., Chicago, IL) software, and 
the plots were constructed using Microsoft Office 2013 
(Microsoft Corporation). The research was approved by 
Research Ethics Committee of the Faculty of Medical Sci-
ences, University of Campinas (number 909/2013).
RESULTS
From 2005-2012, 52,261 samples of nasopharyngeal 
secretions were collected, of which 2,715 [5.8%; 95% 
confidence interval (CI) 5.6-6.0] were positive for RSV. 
The number of samples collected from children under 
5 years old was 12,501, of which 1,373 (11.6%; 95% CI 
11.0-12.2) were positive for RSV.
The ratio of positive results from IIF assays in the 
age group under 5 years old for each of the five regions 
is shown in Table I.
Seasonality: time series - wavelet and Fourier analy-
sis - Wavelet analysis permitted identifying a strong ten-
dency for RSV annual cycles in all regions of the coun-
try; in addition one can suspect a lower second wave 
peak, especially in the early years of the series. It is un-
stable and not statistical significant, but present in Figs 
1-3. This evidence may indicate a biannual (semiannual) 
periodicity, that is, six months after the main peak. This 
second peak is more evident in the North and Midwest 
regions in specific years (Fig. 1).
Fig. 1: time series of the indicator: monthly positivity of samples for respiratory syncytial virus identified by indirect immunofluorescence 
and divided by the number of monthly valid samples, wavelets (left), and significance spectrum (right) in the five regions of Brazil between 
2005-2012. (A) Wavelet power spectra (left): darker areas correspond to higher intensity of the seasonal signal; pink contours show statistically 
significant areas (alpha = 5%); the red line delimits the region not influenced by the edge effects; the timescale on the left represents the time in 
years in an algorithmic scale of base 2. (B) Global wavelet spectrum (black line) with a significance limit of alpha = 5% (pink).
RSV seasonality • André Ricardo Ribas Freitas, Maria Rita Donalisio 297
As shown in Fig. 1, there is a seasonal pattern evi-
denced by the wavelets. Any irregularity may be due to 
the small number of monthly samples.
The same annual cycle pattern with a small peak 
appearing after 6 months can also be observed in Fig. 
2, corresponding to the hospitalisation rates for bron-
chiolitis and pneumonia. These stable annual activity 
patterns identified using wavelets allow the analysis by 
means of Fourier decomposition of the complete time 
series for years 2005-2012.
TABLE I
Positivity for respiratory syncytial virus from indirect immunofluorescence assays of samples of nasopharyngeal secretions  
collected by the SIVEP-GRIPE between 2005 and 2012 in infants less than 5 years old for the five administrative regions of Brazil





North 4139 386 9.6 8.7 - 10.5
Northeast 4112 269 7.1 6.3 - 7.9
Midwest 876 60 7.1 5.5 - 9.0
Southeast 2848 564 21.4 19.8 - 23
South 526 94 18.8 15.6 - 22.5
Global total 12501 1373 11.61 11 - 12.2
*number of positive samples divided by the total number of samples (positive and negative), excluding inadequate samples and 
samples with inconclusive results.
Fig. 2: time series of the monthly hospitalisation rates in infants under the age of 5 years due to bronchiolitis and pneumonia associated with 
respiratory syncytial virus (per 100,000 inhabitants), in the wavelet time series (left) and significance spectrum (right) in five regions of Brazil 
during 2005-2012. (A) Wavelet power spectra (left): darker areas correspond to a higher intensity of the seasonal signal; pink contours show 
statistically significant areas (alpha = 5%); the red line delimits the region not influenced by the edge effects; the timescale on the left represents 
the time in years in an algorithmic scale of base 2. (B) Global wavelet spectrum (black line) with a significance limit of alpha = 5% (pink).
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RSV seasonality analysis through Fourier decompo-
sition of the time series assay results allowed identifying 
regional differences between the greater activity periods in 
the distinct regions of Brazil. The RSV peak occurred in 
the North and Midwest regions in the second week of April 
(peak = 4.4), in the Northeast in the first week of May (peak 
Fig. 3: temporal trend of sample positivity (indirect immunofluorescence) for respiratory syncytial virus, hospitalisation rates for RSV-associ-
ated bronchiolitis and pneumonia, and suggested periods for RSV infection prophylaxis with immunobiologicals for the five regions of Brazil. 
Jointly displays the temporal distribution of the different RSV indicators in the five regions of Brazil. The grey strips indicate the most appropri-
ate periods for immunobiological prophylaxis in each region of the country.
TABLE II
Month and monthly ratio of respiratory syncytial virus activity peaks following different criteria:  
Fourier analysis of the sample positivity, hospitalisation for bronchiolitis or pneumonia associated with RSV,  




































In bracket - larger and smaller values found in each region. *number of monthly indirect immunofluorescence positive samples/
monthly valid samples, Fourier decomposition; **rate of hospitalisation for bronchiolitis and pneumonia associated with RSV, 
Fourier decomposition; ***median of the indicator IIF positive samples/annual positive samples.
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TABLE III
Optimal months for starting prophylaxis against respiratory syncytial virus with palivizumab, according to our indicators* and 
prescription of Brazilian Ministry of Health, in the five regions of Brazil






*positivity monthly, hospitalisation and month with the highest positivity.
= 5.1), in the Southeast in the beginning of April, and in the 
South in the first week of June (peak = 6.2; Table II).
The seasonality Fourier decomposition analysis of 
the monthly rates of hospitalisation for RSV-associated 
bronchiolitis and pneumonia showed similar results when 
compared with the results from the positivity series of as-
says in the same region (Table II). In general, the criteria 
are mutually consistent, with matching results.
Transmission peaks and annual season analysis - 
The most appropriate dates for starting immunoprophy-
laxis with palivizumab for each region of Brazil are com-
pared with the recent indication by Brazilian Ministry of 
Health (Table III). There are differences in the months 
suggested for the beginning of therapy with palivizumab 
in Southeast and Midwest region when compared with 
Brazilian official guidelines.
DISCUSSION
The analysis of the data collected by the SIVEP-
GRIPE between the years 2005-2012 shows a clear sea-
sonality in all regions of Brazil and regional differences 
between the periods of higher viral activity.
The probable RSV seasonal periods identified through 
samples tested by using IIF and from hospitalisation data 
showed similar results. Although the etiologic diagnosis 
of bronchiolitis is not always routinely performed in Bra-
zilian hospitals, it is believed that RSV is responsible for 
60-75% of the total number of cases of this syndrome in 
children under 5 years old (Nair et al. 2010). Thus we 
considered the diagnosis of bronchiolithis and pneumo-
nia due to RSV as a viral circulation marker.
Several studies have demonstrated a strong correlation 
between the hospitalisations for bronchiolitis and pneu-
monia caused by RSV and the viral circulation of RSV; 
this includes using hospitalisation data with codes com-
patible with symptoms caused by RSV as a way of vali-
dating the laboratory surveillance data (Light et al. 2008, 
Panozzo et al. 2010, Hampp et al. 2013). The use of syn-
dormic surveillance, besides validation of laboratory sur-
veillance data, enables identification of underreporting 
or a delay in reporting, through observation of trends 
in the occurrence of the disease (Freitas et al. 2009, van 
den Wijngaard et al. 2012). Accordingly, the seasonality 
matching found through the laboratory and syndrome sur-
veillance indicators are compatible and may validate the 
results. The secondary peaks do not seems to be artifacts.
There has been a great interest in studying RSV 
seasonality in order to develop appropriate prescrip-
tion of palivizumab administration as well as other 
health care actions (Vieira et al. 2001, Paiva et al. 2012, 
Haynes et al. 2013). In Brazil, palivizumab has been 
recommended based on the first studies regarding 
RSV seasonality, mainly performed in the South and 
Southeast states (ANVISA 2011). In 2013, the Brazilian 
Ministry of Health included palivizumab as a drug free-
ly distributed by the Brazilian Public Health System for 
use in premature babies (gestational age less or equal 
than 32 weeks) and infants less than 2 years old with 
chronic lung disease or congenital heart disease with 
demonstrated hemodynamic repercussion. Every state 
and region can establish the optimal period for starting 
the use of immunobiologicals, accounting for the region-
al climate specificities and epidemiological evidences 
(MS 2012). The recent revision of guidelines by the 
Ministry of Health in 2015 proposed a readjustment of 
the periods of provision of immunobiologicals in the dif-
ferent regions of the country (MS 2015). Our results re-
inforce this revision for provision of palivizumab in dif-
ferent regions, as suggested by others studies in Brazil 
(Vieira et al. 2001, Paiva et al. 2012) and others regions 
(Panozzo et al. 2010, Blom-Feshbach et al. 2013). Results 
over the period for availability of palivizumab in the 
Midwest and Southeast (January) do not match exactly 
with those suggested by Ministry of Health (February). 
Although there are differences of one month only, these 
are densely populated regions. The readjustment of the 
immunisation schedule with palivizumab aims to ensure 
the protection of higher risk children, while avoiding the 
waste of this expensive immunobiological.
In addition to ascertaining the optimal time for pro-
phylaxis against RSV, scheduling of other non-pharmaco-
logical interventions can interfere with the transmission 
of RSV. Prevention campaigns among the population and 
health care providers and the planning and provision of 
pediatric hospital beds can be strengthened during these 
periods of the year (Jefferson et al. 2010, CDC 2014).
Some limitations of this study can be indicated, in-
cluding the fact that the data on the positivity for RSV 
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was obtained from an information system, which is still 
only partially and heterogeneously covered in various re-
gions of the country. In addition, during the period stud-
ied, SIVEP-GRIPE did not include other viruses such as 
metapneumovirus, bocavirus, enterovirus, and human 
coronavirus, which may cause similar clinical features. 
Nonetheless, the analysed data represent all the informa-
tion available in SIVEP-GRIPE, having a great implica-
tion on the public health policies in the country. Another 
limitation of this study was the low mean positivity found 
from the tests, which depended on several factors inde-
pendent of the epidemiological situation, such as the qual-
ity of sample collection and transportation, in addition to 
the sensitivity of the test used. Furthermore, the number 
of collected samples did not allow using weekly labora-
tory results or the separate evaluation of the states. How-
ever, the hospitalisation data for bronchiolitis and pneu-
monia due to RSV did not suggest regional discrepancies.
The aggregation of samples in administrative regions 
can lead to inaccurate generalisations, since it does not 
consider differences between the various states that 
make up these regions. However, the reduced number 
of collected samples in some states did not allow this 
separation. Moreover, partial analysis of state data per-
formed in this study showed similar results to those for 
the states aggregated into regions.
The hospitalisation rates for bronchiolitis respiratory 
diseases associated with RSV in children under 5 years 
of age can be considered an indicator that indirectly re-
flects the risk of circulation of RSV in the community, 
although there is no laboratory confirmation of these 
clinical conditions in the routine of hospital care in the 
country. The syndromic surveillance for bronchiolitis 
may be considered a good sentinel indicator of RSV cir-
culation in Brazil. The results of the time series analysis 
of laboratory positivity indicators and hospitalisation re-
inforce the revision and adaptation of provision calendars 
for high-cost immunoprophylaxis and for RSV infection 
prevention campaigns in the different regions of Brazil.
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